This report provides a comprehensive overview of global oncology innovation, access, usage, and spending. It highlights sustained scientific progress despite COVID-19 disruptions, including a rapidly expanding pipeline of nearly 3,500 oncology drugs and increased focus on precision and rare cancers. The report documents reduced screenings and delayed diagnoses during the pandemic, raising concerns about advanced disease presentation. Global oncology spending reached $164 billion in 2020 and is projected to grow through 2025, though at slower rates due to biosimilars and competition. It underscores the importance of early diagnosis, biomarker testing, and equitable access to innovation.

Join for free to read